sale y/i initi ep guid ahead
close pre-announce revenu y/i
ahead estimate street y/i novaseq shipment
high sequenc consum strong y/i vs estimate
y/i consum q/q even excl
stock order also gave initi guid revenu
y/i ahead street estimate still see
initi guid conserv base scenario analysi link given impress
consum ramp bottom line guid adj ep
incl tax reform benefit helix dilut vs estimate street
bullish iseq launch ampliseq deal w/
placement estim order
new-to- custom convers desktop
hiseq hiseqx custom order suggest still
earli stage multi-year adopt cycl also launch iseq origin
unveil firefli new next-gener sequenc system offer
high qualiti reliabl perform desktop system low
cost lower expect small footprint cubic foot
target potenti custom plan open new
market applic particularli infecti diseas surveil furthermor
announc commerci deal sell ion
ampliseq technolog research use ilmn platform order provid
complet workflow solut overal expect see share trade
news given strong sale beat upsid guid solid progress
compani commerci strategi execut reiter buy rate share
rais estim increas po
expect sale y/i y/i
adj ep reiter
buy rate rais po po still dcf-base
wacc termin growth rate
net dbt
guid ahead po reiter buy
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit prospect due wide
adopt compani innov genet
analysi tool strong competit posit
impress forward-look product market
strategi although macro competit risk
remain believ compani recent
launch near-term pipelin help
remain forefront
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim consid
justifi given attract long-term outlook genom market compani
technolog leadership new product cycl increas penetr fast-
grow clinic appli market
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit integr
issu recent manag chang slower-than-expect uptak new product
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
